Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002, for Celsion Corporation (Note: The input metadata lists "Imunon, Inc.", but the filing text explicitly identifies the registrant as Celsion Corporation). The company is a clinical-stage biotechnology firm focused on thermotherapy systems and heat-activated liposomes. It has incurred substantial operating losses since inception and currently generates no product revenue as its new technologies await regulatory approval.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2002 | Six Months Ended Mar 31, 2002 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Net Loss | $(3,741,257) | $(5,394,665) |
| Loss Per Share (Basic) | $(0.04) | $(0.06) |
| Cash and Cash Equivalents | $3,530,095 (as of Mar 31, 2002) | N/A |
| Working Capital | $2,955,021 | N/A |
| Accumulated Deficit | $(39,045,087) | N/A |
| Net Cash Used in Operating Activities | N/A | $(4,537,627) |
Material Changes vs. Prior Period
- Revenue: The company reported zero revenue for the three and six months ended March 31, 2002, compared to $1,858 in the same periods of 2001. No product sales are expected until regulatory approvals are obtained.
- Operating Expenses:
- General and Administrative (G&A): Increased 103% to $1,998,406 (three months) and 33% to $2,539,653 (six months) compared to the prior year. Increases were driven by a legal settlement with Warren C. Stearns, retirement accruals for the former CEO, and consulting costs for potential business expansion in China.
- Research and Development (R&D): Increased 163% to $1,759,775 (three months) and 131% to $2,882,996 (six months). This was due to costs for benign prostatic hyperplasia (BPH) clinical trials, clinical monitoring teams, and engineering for device commercialization.
- Net Loss: The net loss widened significantly to $(3.74) million for the quarter and $(5.39) million for the six-month period, compared to $(1.56) million and $(2.95) million in the prior year, respectively.
- Liquidity: Cash balances increased from $2.51 million (Sept 30, 2001) to $3.53 million (Mar 31, 2002), primarily due to a private placement of equity completed in January 2002.
Guidance, Outlook, and Risks
- Outlook: Management expects operating losses to continue and possibly increase in the near term. The company anticipates expending approximately $7.5 million for the remainder of fiscal year 2002 on R&D and administration.
- Product Pipeline: New equipment is in pivotal Phase II clinical testing. The company plans to accelerate Phase II breast cancer trials and initiate Phase I trials for doxorubicin-laden heat-activated liposomes.
- Capital Needs: The company has no committed sources of additional financing and relies on equity offerings, debt, or strategic alliances to fund operations. If adequate funds are not available, the company may be forced to delay or scale back operations.
- Legal Contingency: A significant lawsuit with Warren C. Stearns was settled in January 2002. The settlement involved issuing 6.3 million warrants and paying up to $265,000 in legal fees, which contributed to the spike in G&A expenses.
Investor Verification Checklist
- Verify the status of the Phase II clinical trials for the BPH device and breast cancer indications.
- Confirm the timeline for FDA submission and potential pre-marketing approval for new thermotherapy systems.
- Assess the sufficiency of the $3.53 million cash balance against the projected $7.5 million expenditure for the remainder of the fiscal year.
- Review the terms of the private placement completed in January 2002 and any subsequent financing activities.
- Monitor the dilution impact of the 6.3 million warrants issued as part of the Stearns legal settlement.